Laminar Therapeutics Stock Is Popping Today: What's Going On?

Impact · against what's priced in

Larimar Therapeutics is seeing a significant price spike driven by bullish analyst reiterations and price target increases from Citigroup and Wedbush. Since the stock is hitting new 52-week highs on this momentum, the news serves as a positive catalyst for short-term valuation expansion.

LRMR+0.60

No priced-in read yet

In context

Citigroup raised its price target to $14 and Wedbush reaffirmed an $11 target, triggering a 72% surge in shares to a new 52-week high.

Read from the article alone

• biotech
• healthcare
• LRMR
• analyst ratings
• bullish
• momentum
• price target
• technical analysis

Search tags